The dual cyclooxygenase/5-lipoxygenase inhibitor licofelone attenuates p-glycoprotein-mediated drug resistance in the injured spinal cord

Journal of Neurotrauma

Volumn 30, Issue 3, 2013, Pages 211-226

  Dulin, Jennifer N ^a   Moore, Meredith L ^a   Grill, Raymond J ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

cervical propriospinal premotoneuronal system; cervical spinal cord injury; forelimb force; kinematics; triceps brachii

Indexed keywords

LICOFELONE; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 1A; RILUZOLE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CONTUSION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; FEMALE; GENE OVEREXPRESSION; MALE; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RAT; REAL TIME POLYMERASE CHAIN REACTION; SPINAL CORD INJURY; TISSUE MICROARRAY; UPREGULATION; WILD TYPE;

EID: 84873325652     PISSN: 08977151     EISSN: 15579042     Source Type: Journal    
DOI: 10.1089/neu.2012.2587     Document Type: Article

References (114)

1. Kwon, B.K., Okon, E., Hillyer, J., Mann, C., Baptiste, D., Weaver, L.C., Fehlings, M.G., and Tetzlaff, W. (2011). A systematic review of non-invasive pharmacologic neuroprotective treatments for acute spinal cord injury. J. Neurotrauma 28, 1545-1588.
2. Gottesman, M.M., Pastan, I., and Ambudkar, S.V. (1996). P-glycoprotein and multidrug resistance. Curr. Opin. Genet. Dev. 6, 610-617. (Pubitemid 26372158)
3. Merino, V., Jime'nez-Torres, N.V., and Merino-Sanjua'n, M. (2004). Relevance of multidrug resistance proteins on the clinical efficacy of cancer therapy. Curr. Drug Deliv. 1, 203-212.
4. Fromm, M.F. (2004). Importance of P-glycoprotein at blood-tissue barriers. Trends Pharmacol. Sci. 25, 423-429. (Pubitemid 38981558)
5. Begley, D.J. (2005). P-glycoprotein: the prototypical BBB efflux transporter, in: Efflux Transporters and the Blood-Brain Barrier. E.M. Taylor (ed). Nova Science Publishers, Inc.: New York, pps. 107-135.
6. Baldini, N., Scotlandi, K., Barbanti-Brodano, G., Manara, M.C., Maurici, D., Bacci, G., Bertoni, F., Picci, P., Sottili, S., Campanacci, M., and Serra, M. (1995). Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome. N. Engl. J. Med. 333, 1380-1385.
7. Marie, J.P., Zittoun, R., and Sikic, B.I. (1991). Multidrug resistance (mdr1) gene expression in adult acute leukemias: correlations with treatment outcome and in vitro drug sensitivity. Blood 78, 586-592.
8. Tan, B., Piwnica-Worms, D., and Ratner, L. (2000). Multidrug resistance transporters and modulation. Curr. Opin. Oncol. 12, 450-458. (Pubitemid 32268882)
9. Milane, A., Fernandez, C., Dupuis, L., Buyse, M., Loeffler, J.P., Farinotti, R., Meininger, V., and Bensimon, G. (2010). P-glycoprotein expression and function are increased in an animal model of amyotrophic lateral sclerosis. Neurosci. Lett. 472, 166-170.
10. Spudich, A., Kilic, E., Xing, H., Kilic, U., Rentsch, K.M., Wunderli-Allenspach, H., Bassetti, C.L., and Hermann, D.M. (2006). Inhibition of multidrug resistance transporter-1 facilitates neuroprotective therapies after focal cerebral ischemia. Nat. Neurosci. 9, 487-488.
11. Agarwal, S., Hartz, A.M., Elmquist, W.F., and Bauer, B. (2011). Breast cancer resistance protein and P-glycoprotein in brain cancer: two gatekeepers team up. Curr. Pharm. Des. 17, 2793-2802.
12. de Klerk, O.L., Willemsen, A.T., Bosker, F.J., Bartels, A.L., Hendrikse, N.H., den Boer, J.A., and Dierckx, R.A. (2010). Regional increase in P-glycoprotein function in the blood-brain barrier of patients with chronic schizophrenia: a PET study with [(11)C]verapamil as a probe for P-glycoprotein function. Psychiatry Res. 183, 151-156.
13. Breedveld, P., Beijnen, J.H., and Schellens, J.H. (2006). Use of Pglycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs. Trends Pharmacol. Sci. 27, 17-24. (Pubitemid 43063120)
14. Bauer, B., Hartz, A.M., Pekcec, A., Toellner, K., Miller, D.S., and Potschka, H. (2008). Seizure-induced up-regulation of P-glycoprotein at the blood-brain barrier through glutamate and cyclooxygenase-2 signaling. Mol. Pharmacol. 73, 1444-1453. (Pubitemid 351574834)
15. Potschka, H. (2010). Targeting regulation of ABC efflux transporters in brain diseases: a novel therapeutic approach. Pharmacol. Ther. 125, 118-127.
16. Amar, A.P., and Levy, M.L. (1999). Pathogenesis and pharmacological strategies for mitigating secondary damage in acute spinal cord injury. Neurosurgery 44, 1027-1039.
17. Tator, C.H. (1996). Experimental and clinical studies of the pathophysiology and management of acute spinal cord injury. J. Spinal Cord Med. 19, 206-214. (Pubitemid 126768336)
18. Tator, C.H. (1998). Biology of neurological recovery and functional restoration after spinal cord injury. Neurosurgery 42, 696-707.
19. Young, W., and Bracken, M.B. (1992). The Second National Acute Spinal Cord Injury Study. J. Neurotrauma 9, Suppl 1, S397-405.
20. Zeidman, S.M., Ling, G.S., Ducker, T.B., and Ellenbogen, R.G. (1996). Clinical applications of pharmacologic therapies for spinal cord injury. J. Spinal Disord. 9, 367-380. (Pubitemid 26423730)
21. Bracken, M.B., Shepard, M.J., Hellenbrand, K.G., Collins, W.F., Leo, L.S., Freeman, D.F., Wagner, F.C., Flamm, E.S., Eisenberg, H.M., Goodman, J.H., Perot, P.L., Jr., Green, B.A., Grossman, R.G., Meagher, J.N., Young, W., Fischer, B., Clifton, G.L., Hunt, W.E., and Rifkinson, N. (1985). Methylprednisolone and neurological function 1 year after spinal cord injury. Results of the National Acute Spinal Cord Injury Study. J. Neurosurg. 63, 704-713. (Pubitemid 16198957)
22. Bracken, M.B., Shepard, M.J., Collins, W.F., Jr., Holford, T.R., Baskin, D.S., Eisenberg, H.M., Flamm, E., Leo-Summers, L., Maroon, J.C., Marshall, L.F., Perot, P.L., Jr., Piepmeier, J., Sonntag, V., Wagner, F.C., Jr., Wilberger, J.L., Winn, H.R., and Young, W. (1992). Methylprednisolone or naloxone treatment after acute spinal cord injury: 1-year follow-up data. Results of the second National Acute Spinal Cord Injury Study. J. Neurosurg. 76, 23-31.
23. Bracken, M.B., Shepard, M.J., Collins, W.F., Holford, T.R., Young, W., Baskin, D.S., Eisenberg, H.M., Flamm, E., Leo-Summers, L., Maroon, J.,Marshall, L.F., Perot, P.L., Jr., Piepmeier, J., Sonntag, V., Wagner, F.C., Wilberger, J.E., and Winn, H.R. (1990). A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury. Results of the Second National Acute Spinal Cord Injury Study. N. Engl. J. Med. 322, 1405-1411. (Pubitemid 20152525)
24. Hurlbert, R.J., and Hamilton, M.G. (2008). Methylprednisolone for acute spinal cord injury: 5-year practice reversal. Can. J. Neurol. Sci. 35, 41-45. (Pubitemid 351518287)
25. Tator, C.H. (2006). Review of treatment trials in human spinal cord injury: issues, difficulties, and recommendations. Neurosurgery 59, 957-982. (Pubitemid 44852056)
26. Bracken, M.B., Shepard, M.J., Holford, T.R., Leo-Summers, L., Aldrich, E.F., Fazl, M., Fehlings, M.G., Herr, D.L., Hitchon, P.W., Marshall, L.F., Nockels, R.P., Pascale, V., Perot, P.L., Jr., Piepmeier, J., Sonntag, V.K., Wagner, F., Wilberger, J.E., Winn, H.R., and Young, W. (1998). Methylprednisolone or tirilazad mesylate administration after acute spinal cord injury: 1-year follow up. Results of the third National Acute Spinal Cord Injury randomized controlled trial. J. Neurosurg. 89, 699-706. (Pubitemid 28485526)
27. Hawryluk, G.W., Rowland, J., Kwon, B.K., and Fehlings, M.G. (2008). Protection and repair of the injured spinal cord: a review of completed, ongoing, and planned clinical trials for acute spinal cord injury. Neurosurg. Focus 25, E14.
28. Saitoh, H., Hatakeyama, M., Eguchi, O., Oda, M., and Takada, M. (1998). Involvement of intestinal P-glycoprotein in the restricted absorption of methylprednisolone from rat small intestine. J. Pharm. Sci. 87, 73-75. (Pubitemid 28079264)
29. Koszdin, K.L., Shen, D.D., and Bernards, C.M. (2000). Spinal cord bioavailability of methylprednisolone after intravenous and intrathecal administration: the role of P-glycoprotein. Anesthesiology 92, 156-163. (Pubitemid 30027460)
30. Bernards, C.M. (2006). Cyclosporine-A-mediated inhibition of pglycoprotein increases methylprednisolone entry into the central nervous system. Spinal Cord 44, 414-420. (Pubitemid 44015136)
31. Festoff, B.W., Ameenuddin, S., Arnold, P.M., Wong, A., Santacruz, K.S., and Citron, B.A. (2006). Minocycline neuroprotects, reduces microgliosis, and inhibits caspase protease expression early after spinal cord injury. J. Neurochem. 97, 1314-1326. (Pubitemid 43725571)
32. Lee, S.M., Yune, T.Y., Kim, S.J., Park, D.W., Lee, Y.K., Kim, Y.C., Oh, Y.J., Markelonis, G.J., and Oh, T.H. (2003). Minocycline reduces cell death and improves functional recovery after traumatic spinal cord injury in the rat. J. Neurotrauma 20, 1017-1027. (Pubitemid 37288561)
33. Stirling, D.P., Khodarahmi, K., Liu, J., McPhail, L.T., McBride, C.B., Steeves, J.D., Ramer, M.S., and Tetzlaff, W. (2004). Minocycline treatment reduces delayed oligodendrocyte death, attenuates axonal dieback, and improves functional outcome after spinal cord injury. J. Neurosci. 24, 2182-2190. (Pubitemid 38314550)
34. Yune, T.Y., Lee, J.Y., Jung, G.Y., Kim, S.J., Jiang, M.H., Kim, Y.C., Oh, Y.J., Markelonis, G.J., and Oh, T.H. (2007). Minocycline alleviates death of oligodendrocytes by inhibiting pro-nerve growth factor production in microglia after spinal cord injury. J. Neurosci. 27, 7751-7761. (Pubitemid 47093808)
35. Marchand, F., Tsantoulas, C., Singh, D., Grist, J., Clark, A.K., Bradbury, E.J., and McMahon, S.B. (2009). Effects of Etanercept and Minocycline in a rat model of spinal cord injury. Eur. J. Pain 13, 673-681.
36. University of Calgary. (2007). Minocycline and Perfusion Pressure Augmentation in Acute Spinal Cord Injury. Available at: http:// clinicaltrials.gov/show/NCT00559494 NLM Identifier: NCT00559494. Accessed August 26, 2012.
37. Milane, A., Fernandez, C., Vautier, S., Bensimon, G., Meininger, V., and Farinotti, R. (2007). Minocycline and riluzole brain disposition: interactions with p-glycoprotein at the blood-brain barrier. J. Neurochem. 103, 164-173. (Pubitemid 47404226)
38. Fehlings, M.G., and Agrawal, S. (1995). Role of sodium in the pathophysiology of secondary spinal cord injury. Spine (Phila Pa 1976) 20, 2187-2191.
39. Schwartz, G., and Fehlings, M.G. (2001). Evaluation of the neuroprotective effects of sodium channel blockers after spinal cord injury: improved behavioral and neuroanatomical recovery with riluzole. J. Neurosurg. 94, 245-256. (Pubitemid 32786052)
40. Schwartz, G., and Fehlings, M.G. (2002). Secondary injury mechanisms of spinal cord trauma: a novel therapeutic approach for the management of secondary pathophysiology with the sodium channel blocker riluzole. Prog Brain Res 137, 177-190. (Pubitemid 35460945)
41. Wang, S.J., Wang, K.Y., and Wang, W.C. (2004). Mechanisms underlying the riluzole inhibition of glutamate release from rat cerebral cortex nerve terminals (synaptosomes). Neuroscience 125, 191-201.
42. Hama, A., and Sagen, J. (2011). Antinociceptive effect of riluzole in rats with neuropathic spinal cord injury pain. J. Neurotrauma 28, 127-134.
43. Kitzman, P.H. (2009). Effectiveness of riluzole in suppressing spasticity in the spinal cord injured rat. Neurosci. Lett. 455, 150-153.
44. The Methodist Hospital System. (2009). Safety of Riluzole in Patients With Acute Spinal Cord Injury. Available at: http://clinical trials.gov/show/NCT00876889 NLM Identifier: NCT00876889. Accessed August 26, 2012.
45. Fehlings, M.G., Tator, C.H., and Linden, R.D. (1989). The effect of nimodipine and dextran on axonal function and blood flow following experimental spinal cord injury. J. Neurosurg. 71, 403-416. (Pubitemid 19225554)
46. Petitjean, M.E., Pointillart, V., Dixmerias, F., Wiart, L., Sztark, F., Lassié, P., Thicoi?pé, M., and Dabadie, P. (1998). Medical treatment of spinal cord injury in the acute stage [in French]. Ann. Fr. Anesth. Reanim. 17, 114-122. (Pubitemid 28175398)
47. Pointillart, V., Petitjean, M.E., Wiart, L., Vital, J.M., Lassié, P., Thicoi?pé, M., and Dabadie, P. (2000). Pharmacological therapy of spinal cord injury during the acute phase. Spinal Cord 38, 71-76. (Pubitemid 30153991)
48. Zhang, L., Liu, X.D., Xie, L., and Wang, G.J. (2003). P-glycoprotein restricted transport of nimodipine across blood-brain barrier. Acta Pharmacol. Sin. 24, 903-906.
49. Baastrup, C., and Finnerup, N.B. (2008). Pharmacological management of neuropathic pain following spinal cord injury. CNS Drugs 22, 455-475. (Pubitemid 351693689)
50. Wiffen, P.J., Derry, S., and Moore, R.A. (2011). Lamotrigine for acute and chronic pain. Cochrane Database Syst. Rev. 2, CD006044.
51. Luna-Tortó s, C., Fedrowitz, M., and Lo?scher, W. (2008). Several major antiepileptic drugs are substrates for human P-glycoprotein. Neuropharmacology 55, 1364-1375.
52. Potschka, H., Fedrowitz, M., and Lo?scher, W. (2002). P-Glycoprotein-mediated efflux of phenobarbital, lamotrigine, and felbamate at the blood-brain barrier: evidence from microdialysis experiments in rats. Neurosci. Lett. 327, 173-176. (Pubitemid 34756625)
53. Uhr, M., Steckler, T., Yassouridis, A., and Holsboer, F. (2000). Penetration of amitriptyline, but not of fluoxetine, into brain is enhanced in mice with blood-brain barrier deficiency due to mdr1a Pglycoprotein gene disruption. Neuropsychopharmacology 22, 380-387. (Pubitemid 30105766)
54. Jablonski, M.R., Jacob, D.A., Campos, C., Miller, D.S., Maragakis, N.J., Pasinelli, P., and Trotti, D. (2012). Selective increase of two ABC drug efflux transporters at the blood-spinal cord barrier suggests induced pharmacoresistance in ALS. Neurobiol. Dis. 47, 194-200.
55. Coley, H.M. (2010). Overcoming multidrug resistance in cancer: clinical studies of p-glycoprotein inhibitors. Methods Mol. Biol. 596, 341-358.
56. Potschka, H. (2010). Modulating P-glycoprotein regulation: future perspectives for pharmacoresistant epilepsies? Epilepsia 51, 1333-1347.
57. Liu, B., Qu, L., and Tao, H. (2009). Cyclo-oxygenase 2 up-regulates the effect of multidrug resistance. Cell Biol. Int. 34, 21-25.
58. Szczuraszek, K., Materna, V., Halon, A., Mazur, G., Wro'bel, T., Kuliczkowski, K., Maciejczyk, A., Zabel, M., Drag, M., Dietel, M., Lage, H., and Surowiak, P. (2009). Positive correlation between cyclooxygenase-2 and ABC-transporter expression in non-Hodgkin's lymphomas. Oncol. Rep. 22, 1315-1323.
59. Xia, W., Zhao, T., Lv, J., Xu, S., Shi, J., Wang, S., Han, X., and Sun, Y. (2009). Celecoxib enhanced the sensitivity of cancer cells to anticancer drugs by inhibition of the expression of P-glycoprotein through a COX-2-independent manner. J. Cell. Biochem. 108, 181-194.
60. Ye, C.G., Wu, W.K., Yeung, J.H., Li, H.T., Li, Z.J., Wong, C.C., Ren, S.X., Zhang, L., Fung, K.P., and Cho, C.H. (2011). Indomethacin and SC236 enhance the cytotoxicity of doxorubicin in human hepatocellular carcinoma cells via inhibiting P-glycoprotein and MRP1 expression. Cancer Lett. 304, 90-96.
61. Zrieki, A., Farinotti, R., and Buyse, M. (2008). Cyclooxygenase inhibitors down regulate P-glycoprotein in human colorectal Caco-2 cell line. Pharm. Res. 25, 1991-2001.
62. Rafati, D.S., Geissler, K., Johnson, K., Unabia, G., Hulsebosch, C., Nesic-Taylor, O., and Perez-Polo, J.R. (2008). Nuclear factorkappaB decoy amelioration of spinal cord injury-induced inflammation and behavior outcomes. J. Neurosci. Res. 86, 566-580. (Pubitemid 351204470)
63. Resnick, D.K., Graham, S.H., Dixon, C.E., and Marion, D.W. (1998). Role of cyclooxygenase 2 in acute spinal cord injury. J. Neurotrauma 15, 1005-1013. (Pubitemid 28560043)
64. Rainsford, K.D. (2007). Anti-inflammatory drugs in the 21st century. Subcell. Biochem. 42, 3-27.
65. Smith, W.L., DeWitt, D.L., and Garavito, R.M. (2000). Cyclooxygenases: structural, cellular, and molecular biology. Annu. Rev. Biochem. 69, 145-182.
66. Fiorucci, S., Meli, R., Bucci, M., and Cirino, G. (2001). Dual inhibitors of cyclooxygenase and 5-lipoxygenase. A new avenue in anti-inflammatory therapy? Biochem. Pharmacol. 62, 1433-1438. (Pubitemid 33145286)
67. Hirsch, F.R., and Lippman, S.M. (2005). Advances in the biology of lung cancer chemoprevention. J. Clin. Oncol. 23, 3186-3197. (Pubitemid 46211343)
68. Mao, J.T., Tsu, I.H., Dubinett, S.M., Adams, B., Sarafian, T., Baratelli, F., Roth, M.D., and Serio, K.J. (2004). Modulation of pulmonary leukotriene B4 production by cyclooxygenase-2 inhibitors and lipopolysaccharide. Clin. Cancer Res. 10, 6872-6878. (Pubitemid 39383036)
69. Mao, J.T., Roth, M.D., Serio, K.J., Baratelli, F., Zhu, L., Holmes, E.C., Strieter, R.M., and Dubinett, S.M. (2003). Celecoxib modulates the capacity for prostaglandin E2 and interleukin-10 production in alveolar macrophages from active smokers. Clin. Cancer Res. 9, 5835-5841. (Pubitemid 38018065)
70. Okunishi, K., and Peters-Golden, M. (2011). Leukotrienes and airway inflammation. Biochim. Biophys. Acta 1810, 1096-1102.
71. Szczeklik, A. (1997). Mechanism of aspirin-induced asthma. Allergy 52, 613-619. (Pubitemid 27286674)
72. Ye, Y.N., Wu, W.K., Shin, V.Y., Bruce, I.C., Wong, B.C., and Cho, C.H. (2005). Dual inhibition of 5-LOX and COX-2 suppresses colon cancer formation promoted by cigarette smoke. Carcinogenesis 26, 827-834. (Pubitemid 41214346)
73. Alvaro-Gracia, J.M. (2004). Licofelone -clinical update on a novel LOX/COX inhibitor for the treatment of osteoarthritis. Rheumatology (Oxford) 43, Suppl. 1, i21-25. (Pubitemid 38219704)
74. Cicero, A.F., and Laghi, L. (2007). Activity and potential role of licofelone in the management of osteoarthritis. Clin. Interv. Aging 2, 73-79.
75. Geurts, A.M., Cost, G.J., Re'my, S., Cui, X., Tesson, L., Usal, C., Me'noret, S., Jacob, H.J., Anegon, I., and Buelow, R. (2010). Generation of gene-specific mutated rats using zinc-finger nucleases. Methods Mol. Biol. 597, 211-225.
76. Herrera, J.J., Haywood-Watson, R.J., 2nd, and Grill, R.J. (2010). Acute and chronic deficits in the urinary bladder after spinal contusion injury in the adult rat. J. Neurotrauma 27, 423-431.
77. Dulin, J.N., Moore, M.L., Gates, K.W., Queen, J.H., and Grill, R.J. (2011). Spinal cord injury causes sustained disruption of the blood-testis barrier in the rat. PLoS One 6, e16456.
78. Scheff, S.W., Rabchevsky, A.G., Fugaccia, I., Main, J.A., and Lumpp, J.E., Jr. (2003). Experimental modeling of spinal cord injury: characterization of a force-defined injury device. J. Neurotrauma 20, 179-193. (Pubitemid 36292827)
79. Basso, D.M., Beattie, M.S., and Bresnahan, J.C. (1995). A sensitive and reliable locomotor rating scale for open field testing in rats. J. Neurotrauma 12, 1-21.
80. Maltese, A., Maugeri, F., Drago, F., and Bucolo, C. (2005). Simple determination of riluzole in rat brain by high-performance liquid chromatography and spectrophotometric detection. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 817, 331-334. (Pubitemid 40431000)
81. Colovic, M., Zennaro, E., and Caccia, S. (2004). Liquid chromatographic assay for riluzole in mouse plasma and central nervous system tissues. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 803, 305-309. (Pubitemid 38452452)
82. Beggs, J.L., and Waggener, J.D. (1976). Transendothelial vesicular transport of protein following compression injury to the spinal cord. Lab. Invest. 34, 428-439.
83. Noble, L.J., Mautes, A.E., and Hall, J.J. (1996). Characterization of the microvascular glycocalyx in normal and injured spinal cord in the rat. J. Comp. Neurol. 376, 542-556. (Pubitemid 27009839)
84. Noble, L.J., and Wrathall, J.R. (1989). Distribution and time course of protein extravasation in the rat spinal cord after contusive injury. Brain Res. 482, 57-66. (Pubitemid 19063150)
85. Sinescu, C., Popa, F., Grigorean, V.T., Onose, G., Sandu, A.M., Popescu, M., Burnei, G., Strambu, V., and Popa, C. (2010). Molecular basis of vascular events following spinal cord injury. J. Med. Life 3, 254-261.
86. Cordon-Cardo, C., O'Brien, J.P., Casals, D., Rittman-Grauer, L., Biedler, J.L., Melamed, M.R., and Bertino, J.R. (1989). Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc. Natl. Acad. Sci. U. S. A. 86, 695-698. (Pubitemid 19037807)
87. van Vliet, E.A., Zibell, G., Pekcec, A., Schlichtiger, J., Edelbroek, P.M., Holtman, L., Aronica, E., Gorter, J.A., and Potschka, H. (2010). COX-2 inhibition controls P-glycoprotein expression and promotes brain delivery of phenytoin in chronic epileptic rats. Neuropharmacology 58, 404-412.
88. Hartz, A.M., and Bauer, B. (2011). ABC transporters in the CNS -An inventory. Curr. Pharm. Biotechnol. 12, 656-673.
89. Doble, A. (1996). The pharmacology and mechanism of action of riluzole. Neurology 47, S233-241. (Pubitemid 26422576)
90. Pan, W., Kastin, A.J., Gera, L., and Stewart, J.M. (2001). Bradykinin antagonist decreases early disruption of the blood-spinal cord barrier after spinal cord injury in mice. Neurosci. Lett. 307, 25-28. (Pubitemid 32539300)
91. Pan, W., and Kastin, A.J. (2001). Increase in TNFalpha transport after SCI is specific for time, region, and type of lesion. Exp. Neurol. 170, 357-363. (Pubitemid 32758688)
92. Pan, W., Csernus, B., and Kastin, A.J. (2003). Upregulation of p55 and p75 receptors mediating TNF-Alpha transport across the injured blood-spinal cord barrier. J. Mol. Neurosci. 21, 173-184. (Pubitemid 37421620)
93. Chu, X., Zhang, Z., Yabut, J., Horwitz, S., Levorse, J., Li, X.Q., Zhu, L., Lederman, H., Ortiga, R., Strauss, J., Li, X., Owens, K.A., Dragovic, J., Vogt, T., Evers, R., and Shin, M.K. (2012). Characterization of multidrug resistance 1a/P-glycoprotein knockout rats generated by zinc finger nucleases. Mol. Pharmacol. 81, 220-227.
94. Pekcec, A., Unkru? er, B., Schlichtiger, J., Soerensen, J., Hartz, A.M., Bauer, B., van Vliet, E.A., Gorter, J.A., and Potschka, H. (2009). Targeting prostaglandin E2 EP1 receptors prevents seizure-Associated P-glycoprotein up-regulation. J. Pharmacol. Exp. Ther. 330, 939-947.
95. Furuno, T., Landi, M.T., Ceroni, M., Caporaso, N., Bernucci, I., Nappi, G., Martignoni, E., Schaeffeler, E., Eichelbaum, M., Schwab, M., and Zanger, U.M. (2002). Expression polymorphism of the blood-brain barrier component P-glycoprotein (MDR1) in relation to Parkinson's disease. Pharmacogenetics 12, 529-534. (Pubitemid 35177082)
96. Vogelgesang, S., Cascorbi, I., Schroeder, E., Pahnke, J., Kroemer, H.K., Siegmund, W., Kunert-Keil, C., Walker, L.C., and Warzok, R.W. (2002). Deposition of Alzheimer's beta-Amyloid is inversely correlated with P-glycoprotein expression in the brains of elderly non-demented humans. Pharmacogenetics 12, 535-541. (Pubitemid 35177083)
97. Langford, D., Grigorian, A., Hurford, R., Adame, A., Ellis, R.J., Hansen, L., and Masliah, E. (2004). Altered P-glycoprotein expression in AIDS patients with HIV encephalitis. J. Neuropathol. Exp. Neurol. 63, 1038-1047. (Pubitemid 39372588)
98. Bartels, A.L., Willemsen, A.T., Kortekaas, R., de Jong, B.M., de Vries, R., de Klerk, O., van Oostrom, J.C., Portman, A., and Leenders, K.L. (2008). Decreased blood-brain barrier P-glycoprotein function in the progression of Parkinson's disease, PSP and MSA. J. Neural. Transm. 115, 1001-1009.
99. Wijnholds, J. (2005). Multidrug resistance-Associated proteins and efflux of organic anions at the blood-brain and blood cerebrospinal fluid barriers, in: Efflux Transporters and the Blood-Brain Barrier. E.M. Taylor (ed). Nova Biomedical Books: New York, pps. 137-156.
100. Hoffmann, K., and Lo?scher, W. (2007). Upregulation of brain expression of P-glycoprotein in MRP2-deficient TR(-) rats resemblesseizure-induced up-regulation of this drug efflux transporter in normal rats. Epilepsia 48, 631-645. (Pubitemid 46587614)
101. Begley, D.J. (2004). ABC transporters and the blood-brain barrier. Curr. Pharm. Des.10, 1295-1312. (Pubitemid 38559749)
102. Kim, W.S., Weickert, C.S., and Garner, B. (2008). Role of ATPbinding cassette transporters in brain lipid transport and neurological disease. J. Neurochem. 104, 1145-1166. (Pubitemid 351293350)
103. Pujol, A., Ferrer, I., Camps, C., Metzger, E., Hindelang, C., Callizot, N., Ruiz, M., Pampols, T., Giros, M., and Mandel, J.L. (2004). Functional overlap between ABCD1 (ALD) and ABCD2 (ALDR) transporters: a therapeutic target for X-Adrenoleukodystrophy. Hum. Mol. Genet. 13, 2997-3006. (Pubitemid 39585232)
104. Khan, M., Singh, J., Gilg, A.G., Uto, T., and Singh, I. (2010). Very long-chain fatty acid accumulation causes lipotoxic response via 5-lipoxygenase in cerebral adrenoleukodystrophy. J. Lipid Res. 51, 1685-1695.
105. Cohen, D.M., Patel, C.B., Ahobila-Vajjula, P., Sundberg, L.M., Chacko, T., Liu, S.J., and Narayana, P.A. (2009). Blood-spinal cord barrier permeability in experimental spinal cord injury: dynamic contrast-enhanced MRI. NMR Biomed. 22, 332-341.
106. Whetstone, W.D., Hsu, J.Y., Eisenberg, M., Werb, Z., and Noble-Haeusslein, L.J. (2003). Blood-spinal cord barrier after spinal cord injury: relation to revascularization and wound healing. J. Neurosci. Res. 74, 227-239. (Pubitemid 37193709)
107. Patel, C.B., Cohen, D.M., Ahobila-Vajjula, P., Sundberg, L.M., Chacko, T., and Narayana, P.A. (2009). Effect of VEGF treatment on the blood-spinal cord barrier permeability in experimental spinal cord injury: dynamic contrast-enhanced magnetic resonance imaging. J. Neurotrauma 26, 1005-1016.
108. Milane, A., Tortolano, L., Fernandez, C., Bensimon, G., Meininger, V., and Farinotti, R. (2009). Brain and plasma riluzole pharmacokinetics: effect of minocycline combination. J. Pharm. Pharm. Sci. 12, 209-217.
109. Segal, J.L., and Brunnemann, S.R. (1989). Clinical pharmacokinetics in patients with spinal cord injuries. Clin. Pharmacokinet. 17, 109-129. (Pubitemid 19199636)
110. Bebawy, M., and Chetty, M. (2009). Gender differences in pglycoprotein expression and function: effects on drug disposition and outcome. Curr. Drug Metab. 10, 322-328.
111. Hong, H., Lu, Y., Ji, Z.N., and Liu, G.Q. (2006). Up-regulation of Pglycoprotein expression by glutathione depletion-induced oxidative stress in rat brain microvessel endothelial cells. J. Neurochem. 98, 1465-1473. (Pubitemid 44200438)
112. Bias, P., Buchner, A., Klesser, B., and Laufer, S. (2004). The gastrointestinal tolerability of the LOX/COX inhibitor, licofelone, is similar to placebo and superior to naproxen therapy in healthy volunteers: results from a randomized, controlled trial. Am. J. Gastroenterol. 99, 611-618. (Pubitemid 38607961)
113. Genovese, T., Mazzon, E., Rossi, A., Di Paola, R., Cannavo, G., Muia, C., Crisafulli, C., Bramanti, P., Sautebin, L., and Cuzzocrea, S. (2005). Involvement of 5-lipoxygenase in spinal cord injury. J. Neuroimmunol. 166, 55-64. (Pubitemid 41074657)
114. Genovese, T., Rossi, A., Mazzon, E., Di Paola, R., Muia, C., Caminiti, R., Bramanti, P., Sautebin, L., and Cuzzocrea, S. (2008). Effects of zileuton and montelukast in mouse experimental spinal cord injury. Br. J. Pharmacol. 153, 568-582. (Pubitemid 351199011)